New app helps people with mental illness shed pounds
NCT ID NCT04560335
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a weight-loss program called CoachToFit for 257 veterans with serious mental illness (like schizophrenia or bipolar disorder) who were obese. Participants used a smartphone app, an activity tracker, and a Bluetooth scale, and worked with a peer coach. The goal was to see if this approach could help them lose weight and improve fitness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CoachToFit app, activity tracker, and Bluetooth scale
- What this could lead to
- If successful, this program could offer a practical, low-cost way to help people with serious mental illness lose weight and improve their health.
- What could go wrong
- This is a completed study, but results may not apply to all groups. Weight loss can be hard to maintain long-term, and the program requires a smartphone and motivation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
257 people
The number who actually took part.
- Started
-
Aug 2021
- Finished
-
Mar 2026
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * chart diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or recurrent major depressive disorder with psychosis; * age 18 and over; * BMI \>= 30.0 (obese); and * ownership of a phone running Android OS or iOS (iPhone). Exclusion Criteria: * chart diagnosis of dementia; * history of bariatric surgery; * pregnant and nursing mothers; * patient has a conservator/legally authorized representative who makes their medical decisions; * psychiatric hospitalization during the month prior to enrollment. Additionally, we will follow the American College of Sports Medicine recommendations for health screening and risk stratification in preparation for starting a moderate intensity exercise program to ensure that participants enrolled are capable of safely engaging in the app's recommendations regarding physical activity. Specifically, all potential participants will be given the Physical Activity Readiness Questionnaire (PAR-Q), a screening tool often used in weight management trials. If they endorse symptoms or major signs suggestive of cardiopulmonary disease (i.e., angina, anginal equivalent, dyspnea, syncope, orthopnea, edema, palpitations or claudication), which is a score \>=1 on the PAR-Q, they will need clearance from a VA physician before enrolling.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Pittsburgh, Pennsylvania, 15240, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five sessions to quiet trauma nightmares in bipolar disorder
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug